RxDoctor Payments Data

Jonah Burke, DO

Family Medicine · Fayetteville, PANPI 1376954586

Payments from drug & device makers

$104in general payments, 2019–2025

Across 7 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$19
  • Johnson & Johnson$18
  • Lilly USA, LLC$17
  • Novo Nordisk$16
  • Ironshore Pharmaceuticals Inc.$12
  • Merck$12
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$104 in reported general payments places this provider in the 30th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$154,907
Medicare patients
506
Services billed
1,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate143$148,671
EliquisApixaban67$89,879
JardianceEmpagliflozin74$86,484
OzempicSemaglutide46$73,660
RybelsusSemaglutide14$33,873
TrulicityDulaglutide13$18,678
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,011
XareltoRivaroxaban12$16,685
Breo ElliptaFluticasone/Vilanterol19$13,881
TradjentaLinagliptin17$12,646
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp24$10,510
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,057
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$8,102
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$8,052
Atorvastatin Calcium513$7,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$12$148,671143 claims
Novo NordiskOzempic, Rybelsus$16$107,53360 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Shingrix$11$49,85196 claims
Lilly USA, LLCTrulicity$17$18,67813 claims
Johnson & JohnsonXarelto$18$16,68512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Fayetteville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →